IL4RA on lymphatic endothelial cells promotes T cell egress during sclerodermatous graft versus host disease

Katia Urso,1 David Alvarez,2 Viviana Cremasco,3 Kelly Tsang,1 Angelo Grauel,1 Robert Lafyatis,4 Ulrich H. von Andrian,2,5 Joerg Ermann,1 and Antonios O. Aliprantis1

1Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital and Harvard Medical School, 2Department of Microbiology and Immunobiology, Harvard Medical School, 3Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, 4Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA. 5Ragon Institute of Massachusetts General Hospital (MGH), MIT, and Harvard, Cambridge, Massachusetts, USA.

Introduction

Systemic sclerosis (SSc) is an autoimmune disorder characterized by inflammation and fibrosis in skin and internal organs. This aggressive disease has the highest mortality rate among all rheumatic diseases (1), but patient heterogeneity and limited insight into pathophysiology have hindered efforts to find effective treatments (2).

Gene expression–profiling studies in lesional skin have identified several molecular subsets of SSc. Most patients with diffuse cutaneous SSc, the most severe form of the disease, fall within 2 groups, diffuse-proliferative and inflammatory, which display upregulation of cell cycle and inflammation-related genes, respectively (3). The sclGvHD mouse model, induced by adoptive transfer of B10.D2 splenocytes into BALB/c Rag2–/– mice, mimics essential SSc manifestations, including skin fibrosis and autoantibody production (4).

We recently demonstrated that the gene expression profile of affected skin in sclGvHD mice strongly resembles the inflammatory subset of SSc, including a prominent signature of IL13-induced genes (5, 6). IL13, along with IL4, activates the type 2 differentiation program in adaptive (i.e., Th2 cells) and innate immune cells (e.g., M2 macrophages, ILC2, mast cells) (7). IL4-receptor α (IL4RA) is the key component of the IL4 and IL13 receptors. In hematopoietic cells, a heterodimer of IL4RA with the common γ-chain is known as the type II IL4/IL13 receptor. While IL4RA has a well-established role in Th2 differentiation and alternative macrophage activation, we report here a previously unappreciated function for IL4RA in lymphatic endothelial cells (LECs): regulation of activated T cell egress.

Seven days after splenocyte transfer, Il4ra–/– hosts had increased numbers of activated graft CD4+ T cells in skin draining lymph nodes (dLNs) but fewer T cells in efferent lymph, blood, and skin. Sphingosine-1 phosphate (S1P), master regulator of lymphocyte egress from LNs, was lower in dLNs of Il4ra–/– hosts with a corresponding decrease of S1P kinase 1 (Sphk1) expression in LECs. Bypassing the efferent lymphatics via i.v. injection of CD4+ T cells from dLNs of Il4ra–/– sclGvHD mice restored clinical GvHD in secondary Il4ra–/– recipients. These results identify a role for IL4RA and suggest that modulation of lymphocyte egress from LNs may be effective in SSc and GvHD.
Here, we report an essential function for IL4RA in skin draining lymph nodes (dLNs) of mice with sclGvHD. Il4ra–/– hosts accumulate more activated graft T cells in dLNs, and fewer of these cells are detectable in the efferent lymph, blood, and skin compared with controls. Mechanistically, IL4RA appears to control the expression of Sphki in LECs during the early phase of sclGvHD. Thus, in the absence of IL4RA, sphingosin-1 phosphate (S1P) levels are reduced in the efferent lymphatics and effector T cells are trapped in dLNs. Taken together, our results identify a role for IL4RA on LECs as a key factor for S1P regulation and for lymphocyte egress, a checkpoint that could be leveraged to control the progression of autoimmune diseases like SSc.

Results

IL4RA-deficient hosts are protected from sclGvHD. Alopecia is a major clinical feature in the sclGvHD model that becomes apparent 3 weeks after transfer of B10.D2 splenocytes into BALB/c Rag2–/– hosts (clinical score 2 = alopecia involving < 25% of body surface) progressing over the next weeks to involve more body surface (clinical score 3 = alopecia involving > 25% of body surface) (4, 5). Host mice lacking IL4RA (sclGvHD Il4ra–/– mice) fail to develop clinical signs of sclGvHD skin disease (Figure 1A) (5). Searching for mechanisms contributing to protection in these mice, we examined sclGvHD Il4ra+/+ and sclGvHD Il4ra–/– hosts on day 7 after splenocyte transfer (referred to hereafter as 7d-sclGvHD and 7d-sclGvHD Il4ra–/– mice, respectively). At this time point, sclGvHD in Il4ra–/– mice is characterized by weight loss and histological skin inflammation, while clinical signs of alopecia have not yet developed (4, 5). Compared with 7d-sclGvHD mice, 7d-sclGvHD Il4ra–/– mice had lost 50% less body weight (Figure 1B), and histological skin inflammation was significantly reduced (Figure 1, C and D) with a significantly lower number of skin-infiltrating CD3+ T cells (Figure 1, E and F). These data demonstrate that IL4RA expression by host cells critically affects the early events in sclGvHD.

Host IL4RA deficiency does not impair alloactivation of graft T cells in skin dLNs. We hypothesized that skin inflammation in 7d-sclGvHD Il4ra–/– hosts might be reduced because of defective priming of alloreactive graft T cells in skin dLNs (10). However, the frequency of activated CD4+CD69+ T cells was similar in the dLNs of 7d-sclGvHD and 7d-sclGvHD Il4ra–/– hosts (Figure 2A), while the proportion of ki67+ proliferating T cells was marginally higher in 7d-sclGvHD Il4ra–/– mice (Figure 2B). There was also no difference in the frequency of effector-memory T cells (TEM cells, CD44+CD62L–) (Figure 2C), the key T cell population in GvHD that migrates from dLNs to the skin to propagate disease (11), suggesting that the priming of alloreactive graft T cells in 7d-sclGvHD Il4ra–/– mice was not impaired. In fact, contrary to our expectation, we found that the total cell count and the number of CD4+ T cells were significantly higher in the dLNs of 7d-sclGvHD Il4ra–/– compared with 7d-sclGvHD mice (Figure 2, D and E). Consistent with this increase in cellularity, dLN weights were also significantly higher in 7d-sclGvHD Il4ra–/– mice (Figure 2F), whereas there was no difference in spleen weights (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/jci.insight.88057DS1).

Egress of activated alloreactive T cells from dLNs is impaired in IL4ra–/– hosts. One potential explanation for finding more T cells in dLNs and fewer T cells in the skin of 7d-sclGvHD Il4ra–/– mice compared with controls would be a defect in lymphocyte trafficking in Il4ra–/– hosts, in particular a defect in lymphocyte egress from the dLNs. To test this hypothesis, we measured T cell numbers in lymph and blood of 7d-sclGvHD and 7d-sclGvHD Il4ra–/– mice. Lymph collected by thoracic duct cannulation from 7d-sclGvHD Il4ra–/– mice contained fewer total cells, mostly due to a marked reduction in CD4+ T cells, which represent about 80% of all cells in the lymph of 7d-sclGvHD mice (Figure 3, A–C). The number of total and CD4+ T cells in the blood of 7d-sclGvHD Il4ra–/– mice was also significantly reduced compared with 7d-sclGvHD mice (Figure 3, D–F). We first considered that the apparent defect in T cell egress from the dLNs in sclGvHD Il4ra–/– mice might be caused by upregulation of retention signals such as CCL19 and CCL21, the ligands of CCR7 (12). However, expression of Ccl19 and Ccl21 measured in whole dLN cDNA preparations by quantitative PCR (qPCR) was lower in 7d-sclGvHD Il4ra–/– dLNs compared with dLNs from 7d-sclGvHD controls (Figure 3, G and H), implying that the increased cellularity of 7d-sclGvHD Il4ra–/– dLNs was not due to upregulation of CCL19 or CCL21 (13).

S1P production is impaired in dLNs of Il4ra–/– hosts. T cell egress from lymph nodes is controlled by S1P signals. Stromal cells secrete S1P, generating a gradient with increasing extracellular S1P levels in the direction of the efferent lymphatic vessels. Early after activation, T cells express low surface levels of the S1P receptor S1PR1. After several rounds of proliferation, expression of S1PR1 on the T cell...
surface is restored, and the S1P concentration gradient guides the T cells out of the dLN into the efferent lymphatics, allowing them to reach the blood circulation and ultimately their target organs (11). A superagonist of the S1PR1 receptor, FTY720, has been shown to inhibit the S1P pathway, resulting in lymphopenia in lymph and blood (14, 15). When we treated sclGvHD mice with FTY720 for 1 week after splenocyte transfer, we observed enhanced accumulation of graft T cells in the dLNs and reduced T cell infiltration in the skin (Figure 4, A and B), similar to the phenotype of sclGvHD Il4ra–/– mice.

Using a previously described bioassay (16, 17), we measured S1P in cell-free extracts of dLNs (LN media) from 7d-sclGvHD and 7d-sclGvHD Il4ra–/– mice. LN media from 7d-sclGvHD Il4ra–/– mice contained significantly less S1P than 7d-sclGvHD controls (Figure 4C). As the concentration of S1P in lymph nodes is generally low except for the medulla (14, 18), the lower S1P concentration in LN media isolated from 7d-sclGvHD Il4ra–/– mice is indicative of a weaker S1P concentration gradient in these mice. There was no difference in S1PR1 surface expression on CD4+ T cells from the dLNs of Il4ra–/– and Il4ra+ hosts (Figure 4D).

Extracellular S1P levels are controlled by the kinases SPHK1 and SPHK2, which generate S1P from membrane-derived sphingosine, the transporter spinster homolog 2 (SPNS2) that mediates S1P secretion...
by LECs (19), as well as enzymes that catalyze S1P degradation, including S1P lyase (SGPL1) and the S1P phosphatases (SGPP1, SGPP2) (20–22). qPCR analysis of total dLN tissue revealed that \( Sphk1 \) mRNA levels were significantly lower (by about 50%) in the dLNs of 7d-sclGvHD \( Il4ra^{-/-} \) mice than 7d-sclGvHD controls (Figure 4E). In contrast, there were no differences in expression levels of \( Sphk2, Spns2, Sgpl1 \), and \( Sgpp1 \) (Supplemental Figure 2, A–D).

**Figure 2. Increased alloreactive CD4⁺ T cells in the dLNs of 7d-sclGvHD \( Il4ra^{-/-} \) mice.** (A–C) Representative FACS plots and quantification of CD4⁺ cells expressing (A) CD69, (B) ki67, or (C) naive/TEM markers (CD44 and CD62L) in the dLNs of 7d-sclGvHD and 7d-sclGvHD \( Il4ra^{-/-} \) mice \((n = 6–7 per group, **P < 0.01, Student’s t test)\). (D and E) Absolute number of (D) total cells and (E) CD4⁺ T cells isolated from the dLNs of 7d-sclGvHD and 7d-sclGvHD \( Il4ra^{-/-} \) mice \((n = 10 per group, ****P < 0.0001 and ***P < 0.001, Student’s t test)\). (F) dLN weight isolated from 7d-sclGvHD and 7d-sclGvHD \( Il4ra^{-/-} \) mice \((n = 8 per group, ***P < 0.001, Student’s t test)\). Data are means ±SD. The graphs represent data pooled from 3 independent experiments.
Sphk1 expression by LECs is reduced in dLNs of Il4ra–/– hosts. We then analyzed the mRNA expression of Sphk1 in sorted cell subsets from dLNs of 7d-sclGvHD and 7d-sclGvHD Il4ra–/– mice. Lymphatic endothelial cells (LECs) and fibroblastic reticular cells (FRCs) were the major populations with detectable amounts of Sphk1 transcript, consistent with previous reports that identified stromal cells as the major source of S1P in naive LNs (17). LECs, but not FRCs, isolated from the dLNs of 7d-sclGvHD Il4ra–/– mice expressed less Sphk1 compared with the same population from 7d-sclGvHD control mice (Figure 5, A–C) while there was no difference in the absolute number of LECs or FRCs recovered from dLNs of both hosts (Figure 5, D and E). Together, these data support the conclusion that the lower S1P concentration in the dLNs of 7d-scl-GvHD Il4ra–/– mice is the result of reduced Sphk1 expression by LECs in these mice. Interestingly, LECs isolated from BALB/c Il4ra+/+ and Il4ra–/– mice (i.e., mice without disease) expressed similar amounts of Sphk1 mRNA after short-term in vitro culture. Stimulation with dLN media from 7d-sclGvHD mice resulted in upregulation of Sphk1 expression in Il4ra–/– LECs (2- to 6-fold in 5 independent experiments). Sphk1 induction was significantly attenuated in Il4ra–/– LECs, consistent with an intrinsic defect of Sphk1 expression in these cells (Figure 5F). LECs have been shown to express IL4RA (23, 24), and stimulation of Il4ra–/– LECs with dLN media from 7d-sclGvHD mice enhanced IL4RA expression (Supplemental Figure 3A).
IL13 induced the expression of Ccl2, a well-known IL13 target gene (Supplemental Figure 3B) but by itself did not result in upregulated Sphk1 transcription in Il4ra+/+ LECs (Figure 5F).

Immunofluorescence microscopy for the LEC marker LYVE-1 revealed a collapsed appearance of the lymphatic vessels in dLNs of 7d-sclGvHD Il4ra–/– mice (Figure 5G). The aspect ratio as a measure of lymphatic vessel compression (25) was significantly higher in dLN sections from 7d-sclGvHD Il4ra–/– mice compared with 7d-sclGvHD controls (Figure 5G). Similar changes in lymphatic vessel morphology have been previously described in mice lacking S1P production by LECs (17) or in mice deficient in the S1P transporter SPNS2 (19). Lymphatic vessel morphology therefore supports the conclusion that there is a functionally relevant decrease in tissue S1P levels in the dLNs of 7d-sclGvHD Il4ra–/– mice. Correspondingly, we found that mRNA expression of VE-Cadherin, a known target gene of S1P signals in endothelial cells (17, 26–29), was significantly lower in 7d-sclGvHD Il4ra–/– dLNs (Figure 5H).

Secondary transfer of dLN T cells from 7d-sclGvHD Il4ra–/– mice into blood partially restores disease in Il4ra–/– hosts. If Il4ra–/– host mice are protected from sclGvHD because the alloreactive T cells are trapped in the dLNs, one would expect that by bypassing this block, one might bring about clinical disease. To test this hypothesis, we isolated CD4+ T cells from dLNs of 7d-sclGvHD Il4ra–/– mice (mostly TEM cells, Supplemental Figure 4) and i.v. injected them into secondary 7d-sclGvHD Il4ra–/– hosts. An additional group of 7d-sclGvHD Il4ra–/– animals received LN cells from B10.D2 mice (mostly naive T cells, Tnaive cells, Supplemental Figure 4) to control for phenotypic effects that were the result of supplying an additional load of alloreactive T cells. During the observation period of 6 weeks, 5/15 (33%) sclGvHD Il4ra–/– mice receiving CD4+ T cells from 7d-sclGvHD Il4ra–/– mice (T_{EM}→sclGvHD Il4ra–) developed alopecia and thus clinical sclGvHD, compared with 0/12 animals receiving CD4+ T cells from B10.D2 donors (T_{naive}→sclGvHD Il4ra–) and 0/7 sclGvHD Il4ra–/– mice not receiving any additional cells (Figure 6, A and B). The number of infiltrating CD3+ T cells was much higher in the skin of T_{EM}→sclGvHD Il4ra–/– mice...
**Figure 5. dLN LECs express less Sphk1 in 7d-sclGvHD Il4ra<sup>−/−</sup> mice.** (A) Representative FACS plot indicating the subsets of CD45<sup>+</sup> dLN cells identified as FRCs (gp38<sup>−</sup>CD31<sup>−</sup>) and LECs (gp38<sup>−</sup>CD31<sup>+</sup>). (B and C) qPCR measuring Sphk1 expression in (B) LECs or (C) FRCs sorted from dLNs of 7d-sclGvHD and 7d-sclGvHD Il4ra<sup>−/−</sup> mice (n = 4 experiments, with 3–5 mice pooled in each experiment, ****P < 0.0001, Student’s t test). (D) Absolute number of LECs isolated in B. (E) Absolute number of FRCs isolated in C. (F) qPCR measuring Sphk1 expression in LECs isolated from the dLN of BALB/c WT or Il4ra<sup>−/−</sup> mice and cultured for 2 hours with either IL13 (20 ng/ml), dLN-media from 7d-sclGvHD (40%), or a combination of them. Data points represent average of individual experiments. Data points comparing WT or Il4ra<sup>−/−</sup> LECs from individual experiments are linked by lines. *P < 0.05, **P < 0.01, 2-way ANOVA for repeated measures followed by Bonferroni post-test. The experiments were performed more than 3 times. (G) Frozen sections of inguinal dLNs isolated from 7d-sclGvHD and 7d-sclGvHD Il4ra<sup>−/−</sup> stained for LECs (LYVE-1<sup>+</sup>, green), T cells (CD3<sup>+</sup>, red), and nuclei (DAPI, blue) (upper panels). Vessels with a defined lumen were outlined and the image dichotomized into luminal (white) and nonluminal (black) areas (lower panels). 40×. Scale bar: 50 μm (n = 43–55 total vessels quantified with Image J Fiji software. The graph on the right represents quantification of the aspect ratios (maximum diameter/minimum diameter) of the lymphatic vessels identified in the left panels. A circular vessel has an aspect ratio of 1. Larger aspect ratios indicate more compressed vessels. n = 5 mice per group; ***P < 0.001; Student’s t test. (H) qPCR measuring VE-Cadherin expression in cDNA prepared from the dLNs of 7d-sclGvHD and 7d-sclGvHD Il4ra<sup>−/−</sup> mice (n = 10 per group, **P < 0.0001, Student’s t test).
(irrespective of clinical alopecia) and was statistically indistinguishable from sclGvHD control mice (Figure 6, C and D). Skin sections of TEM → sclGvHD II4ra−/− mice with alopecia showed fibrosis similar to sclGvHD mice (Figure 6E), providing additional evidence for the restoration of clinical sclGvHD in the TEM → sclGvHD II4ra−/− group.

**Discussion**

Murine sclGvHD and a subset of SSc patients share a signature of IL13-induced genes in the skin (5, 6, 30). Following up on our published observation that mice deficient for IL4RA, a component of the IL13 receptor, are protected from sclGvHD (5), we demonstrate in this study that the IL13/IL4RA pathway is not only important in the skin, but also plays a critical role during the early phase of the pathogenic immune response in skin dLNs. Specifically, we found that impaired egress of alloreactive CD4+ T cells
from dLNs in IL4RA-deficient mice was associated with a defective SPHK1/S1P pathway in LECs and contributed to the protection of IL4RA-deficient hosts from sclGvHD. This conclusion was supported by restoration of skin disease in a substantial number of Il4ra–/– hosts when TEm cells were directly injected into the blood stream.

IL4RA is expressed on multiple cell lineages, including endothelial cells, fibroblasts, and myeloid cells (31–33). The role of IL13 as a local mediator of skin fibrosis in SSc and other diseases is well established (34, 35) and likely involves the activation of dermal fibroblasts and profibrotic macrophages (36). We previously reported that, 2 weeks after splenocyte transfer, the number of CD11b+MHCII+ dermal macrophages (34, 35) and likely involves the activation of dermal fibroblasts and profibrotic macrophages (36). We previously reported that, 2 weeks after splenocyte transfer, the number of CD11b+MHCII+ dermal macrophages (34, 35) and likely involves the activation of dermal fibroblasts and profibrotic macrophages (36). We previously reported that, 2 weeks after splenocyte transfer, the number of CD11b+MHCII+ dermal macrophages (34, 35) and likely involves the activation of dermal fibroblasts and profibrotic macrophages (36) has previously been shown in human lung epithelial cells (37), short-term stimulation of Il4ra–/– LECs with IL13 upregulated the known IL13 target gene Ccl2 but not Sphk1 (Figure 5F and Supplemental Figure 3B). However, stimulation with cell free extract from d7-sclGvHD mice (LN media) resulted in significantly stronger induction of Sphk1 mRNA in Il4ra–/– LEC than in Il4ra–/– LECs (Figure 5F). The induction of Sphk1 mRNA by inflammatory stimuli such as LPS and TGFβ has been described for other cell types (33, 34). Little is known about the signals that regulate Sphk1 mRNA in LECs inside dLNs. Presumably, the absence or presence of IL4RA signals in LECs modulates Sphk1 mRNA expression and S1P production under particular inflammatory conditions; the molecular link between IL4RA and Sphk1 expression still needs to be explored. To conclusively demonstrate that the lymphocyte egress block in Il4ra–/– hosts in the sclGvHD model is mediated specifically via IL4RA deficiency in LECs would require the generation of a host mouse with conditional deletion of Il4ra in LECs. However, the sclGvHD model is highly dependent on the genetic background requiring the combination of a BALB/c host and B10.D2 donor (38). Generation of conditional KO mouse would thus require a substantial breeding effort to generate LYVE-1-cre Rag2–/– mice on a BALB/c background.

Defects in lymphocyte egress from LNs in Il4ra–/– mice have not been reported. However, even germline Sphk1–/– mice do not have a strong defect in lymphocyte egress. This is likely due to compensation via Sphk2 activity, as double-deficient Sphk1–/–Sphk2–/– mice (Sphk2–/– mice that lack Sphk1 expression in LECs) exhibit profound lymphopenia in lymph and blood at steady state (17). We speculate that, during sclGvHD, the modest deficiency in Sphk1 observed in Il4ra–/– hosts becomes relevant because there is no compensatory upregulation of Sphk2 expression under these conditions (Supplemental Figure 2A). Our data suggest that, in the context of certain inflammatory conditions, even modest changes in the concentration of S1P in the efferent lymphatics may be clinically meaningful. The collapsed morphology of the lymphatics in the dLNs of 7d-sclGvHD Il4ra–/– mice, which recapitulates the LN phenotype observed in Sphk1–/–Sphk2–/– and Spns2–/– mice (17, 19), is consistent with this notion. Additional support for the conclusion that the entrapment of T cells in the dLNs of Il4ra–/– hosts is S1P mediated comes from the finding that administration of the S1PR1 superagonist FTY720 to Il4ra–/– hosts resulted in a dLN phenotype similar to Il4ra–/– hosts (Figure 4, A and B). Although we did not analyze the effect of FTY720 administration on the clinical sclGvHD phenotype in Il4ra–/– hosts, our results are consistent with previous studies demonstrating that long-term treatment of irradiated GvHD mice with FTY720 ameliorated the disease (39, 40).

Our study identifies a link between the IL13/IL4RA and S1P pathways in the pathogenesis of scl-GvHD. Since drugs targeting IL13, IL4RA, or the S1P pathway have either been approved or are in late development (20, 41–43), clinical trials with these agents in patients with the inflammatory form of SSc should be a near term goal.
Methods

Mice. Rag2<sup>–/–</sup>Il4ra<sup>+/+</sup> and Rag2<sup>–/–</sup>Il4ra<sup>–/–</sup> mice on a BALB/c genetic background were generated as described previously (5). B10.D2, BALB/c, and BALB/c Il4ra<sup>–/–</sup> mice were purchased from the Jackson Laboratory and maintained inbred in our facility. All mice were housed in a specific pathogen-free animal facility at the Harvard T.H. Chan School of Public Health, and studies were performed according to institutional and NIH guidelines. The drinking water of all Rag2<sup>–/–</sup> mice was supplemented with sulfamethoxazole and trimethoprim (Sulfatrim, Hi-Tech Pharmacal, 0.6 mg/ml drinking solution).

sclGvHD model. Spleens from B10.D2 mice (allogeneic, graft) were gently homogenized, and red blood cells were lysed with BDLyse (BD Biosciences). Approximately 20 × 10<sup>6</sup> to 30 × 10<sup>6</sup> cells were injected i.v. into sex-matched 6- to 8-week-old Rag2<sup>–/–</sup>Il4ra<sup>+/+</sup> and Rag2<sup>–/–</sup>Il4ra<sup>–/–</sup> mice to induce GvHD. In long-term experiments, the mice were scored blindly twice weekly for clinical signs of GvHD using a previously described (5) scoring system: 1 = hunched posture and ruffled fur; 2 = alopecia < 25% of the body surface; 3 = alopecia > 25% of the body surface; 4 = death or a veterinary order for euthanasia. In the indicated experiments, mice were treated daily for 6 days with 3 mg/kg FTY720 (Cayman Chemicals) or saline by oral gavage starting on day 1 after splenocyte transfer.

Collection of thoracic duct lymph and blood. Thoracic duct cannulation surgery and collection of lymph was performed as previously described (44). Briefly, mice were administered olive oil by gavage 1 hour prior to the procedure and then anesthetized by i.p. injection of 100 mg/kg ketamine HCl, 10 mg/kg xylazine, and 3 mg/kg acepromazine. Mice receive a heparinized polyethylene catheter in the left jugular vein prior to the procedure and then anesthetized by i.p. injection of 100 mg/kg ketamine HCl, 10 mg/kg xylazine, and 3 mg/kg acepromazine. Mice were heparinized polyethylene catheter in the left jugular vein for administration of fluids (Ringer's lactate, 1 U/ml heparin) prior to and throughout the thoracic duct cannulation procedure. Thoracic duct lymph was collected for 1 hour via a heparinized cannula inserted into the cisterna chyli and assayed by flow cytometry. A peripheral blood sample was collected from the submandibular vein.

Cell isolation, flow cytometry, and sorting. dLNs (2 inguinal, 2 axillary, 2 brachial, 2 popliteal, and 4 cervical LNs per mouse) were isolated and digested as described (45) in RPMI 1640 with 2% FBS, 0.8 mg/ml Dispase (Roche Diagnostics), 0.2 mg/ml Collagenase P (Roche Diagnostics), and 0.1 mg/ml DNase I (Sigma-Aldrich). Single cell suspensions were stained in the presence of Fc-block with fluorochrome-conjugated antibodies (all purchased from BioLegend unless otherwise indicated) against the following targets: CD4 (RM4-4), CD45 (30-F11), CD3 (145-2C11), TCRb (H57-597), CD44 (IM7), CD62L (MEL-14), CD69 (H.2F3), gp38 (8.1.1), CD31 (MEK13.3), S1PR1 (713412, R&D Systems). Staining with S1PR1 antibody was performed in the presence of fatty acid–free BSA from Sigma-Aldrich; blood cells were used as S1PR negative controls (17, 46). Stained cells were analyzed with the FACS Canto II (BD Biosciences) and FlowJo software. For ki67 (clone 16A8, BioLegend) intracellular staining, cells were fixed and permeabilized with the Foxp3 Fix/Perm Buffer Set (BioLegend). LN stromal cells were sorted as described (45) using a BD FACSAria Fusion cell sorter; CD45<sup>+</sup> cells were depleted prior to sorting with anti-biotin magnetic beads (Miltenyi Biotec).

SIP Bioassay. WEHI-S1PR1-Flag-hCD4 B cells were provided by Joao Pereira (Yale University, New Haven, Connecticut, USA) and cultured in RPMI 1640 supplemented with 10% FBS, 1% penicillin/streptomycin, 1% glutamine, and 0.05 mM β-Mercaptoethanol. To prepare cell-free dLN media, dLNs were isolated from 7d-sclGvHD mice, gently homogenized in 300 μl of RPMI + 0.5% fatty acid-free BSA (Sigma-Aldrich) at 4°C and centrifuged to remove cells and debris. The SIP bioassay was performed as described (16). WEHI-S1PR1-Flag-hCD4 B cells/ml (2 × 10<sup>6</sup>) were incubated with 100% dLN media for 40 minutes at 37°C. S1PR1 surface expression was evaluated on hCD4<sup>+</sup> cells with anti-S1PR1 antibody followed by a fluorochrome-labeled secondary antibody (Jackson ImmunoResearch). Staining with S1PR1 antibody was performed in the presence of fatty acid–free BSA from Sigma-Aldrich; blood cells were used as S1PR negative controls (17, 46). Stained cells were analyzed with the FACS Canto II (BD Biosciences) and FlowJo software. For ki67 (clone 16A8, BioLegend) intracellular staining, cells were fixed and permeabilized with the Foxp3 Fix/Perm Buffer Set (BioLegend). LN stromal cells were sorted as described (45) using a BD FACSAria Fusion cell sorter; CD45<sup>+</sup> cells were depleted prior to sorting with anti-biotin magnetic beads (Miltenyi Biotec).

LEC culture. dLN stromal cells were isolated as previously described (45) from BALB/c WT or Il4ra<sup>–/–</sup> mice. Adherent cells derived from digested dLNs were cultured on plates precoated with 0.5% gelatin (Sigma-Aldrich) in α-MEM media with 10% FBS, 1% penicillin/streptomycin, and 1% l-glutamine. After 4 days, the primary culture consisted mainly of FRCs and LECs (45). LECs were separated by positive selection of CD31<sup>+</sup> cells with the EasySep Mouse Biotin selection kit (Stemcell Technologies) and seeded at 1 × 10<sup>6</sup> cells/ml on 0.5% gelatin precoated plates. LEC purity was assessed by flow cytometry (70%–90% CD31<sup>+</sup>gp38<sup>+</sup> cells). Twenty-four hours later, LECs were starved for 16 hours in 0.5% FBS media and then

[10]
stimulated with IL13 (20 ng/ml, R&D Systems), cell-free dLN media, prepared as for the S1P bioassay (40%) or both for 2 hours.

RNA isolation, qPCR. RNA was extracted from whole dLNs with Trizol reagent (Qiagen). RNA from sorted cells and primary LECs was isolated with the RNeasy Micro kit (Qiagen) following the manufacturer’s instructions. RNA was reverse transcribed with the Affinity Script qPCR CDNA Synthesis Kit (Agilent Technology). qPCR was performed using Sybr green reagent (Invitrogen). Primers are listed in Table 1. Data were normalized to Hprt.

Histology, IHC, and immunofluorescence. Back skin was isolated from sclGvHD mice 7 or 42 days after splenocyte transfer, fixed in 10% formalin, and embedded in paraffin. Two H&E-stained back skin tissue samples per mouse were scored blindly by an observer experienced in SSc pathology (R. Lafyatis) for inflammation, using a semiquantitative scale from 0–3. T cell IHC on paraffin-embedded skin sections was performed using anti-CD3 antibody (A0452, DAKO) following manufacturer’s instructions. The number of infiltrating CD3+ cells was evaluated blindly on 4 representative 20× IHC pictures with Image J software. Collagen was stained with the Masson’s Trichrome staining kit (Polysciences). Frozen sections of skin dLNs were prepared from sucrose saturated, paraformaldehyde fixed tissue embedded in Optimal Cutting Temperature medium. Frozen sections (10μm) were stained with DAPI, (Sigma-Aldrich) FITC-conjugated LYVE-1 antibody (ALY7, eBioscience), and AlexaFluor 594-conjugated CD3 antibody (17A2, BioLegend). Sections were imaged using a Leica SP5X laser-scanning confocal microscope. To determine compression of lymphatic vessels, the images were analyzed with ImageJ/Fiji software, and the aspect ratio was determined for all vessels with a defined lumen by calculating the ratio of maximum to minimum diameters as in ref. 25. An aspect ratio of 1 is a perfectly round vessel, and higher numbers indicate more compressed vessels.

Adoptive transfer of naive or activated TEM cells into 7d-sclGvHD Il4ra–/– mice. CD4+ cells were isolated from dLNs of B10.D2 mice or 7d-sclGvHD Il4ra–/– mice by negative selection with the CD4+ T cells isolation II kit (Miltenyi Biotec). Purity of the cells was assessed by flow cytometry (88%–95% CD4+). Purified CD4+ cells (2 × 10^6 to 3 × 10^6) were injected i.v. into 7d-sclGvHD Il4ra–/– mice. Mice were blindly monitored for clinical signs of GvHD as described and sacrificed on day 42 for histological analysis of the skin.

Statistics. The number of animals to be used in each experiment was estimated using the G*Power 3.1 program, considering a statistical power of 80% and a significance level of 0.05. Experiments with 2 groups were analyzed with unpaired Student’s t tests for continuous variables, and Mann-Whitney U tests were used for categorical values. Two-way ANOVA followed by Bonferroni post-test correction for multiple hypothesis testing was used for experiments with multiple groups. A significance level α = 0.05 was considered significant. Log-rank (Mantel-Cox) test for Kaplan-Meier survival curves was used for the clinical score in Figure 6, and as we compared 2 of the 4 groups, the significance level was adjusted to α = 0.025. All statistical analyses were performed with GraphPad Prism software. Error bars represent ±SD of biological replicates. All experiments were performed at least 3 times unless otherwise indicated.

| Gene | Primer Forward | Primer Reverse |
|------|----------------|----------------|
| Sphk1A | ACTCACCGAAGGAAGAACC | AGTCTGGGCTTCATTAGC |
| Sgpl1A | CTTGTTGCTACAGGTTTGT | GCTTTGCTCACCTGTTGTT |
| Sphk2A | GATGGCCCATTGGTGCTCC | GATGGCCCATTGGTGCTCC |
| Sgpp1A | GTTCGCTCACTAGACCTCC | GCTTTGCTCACCTGTTGTT |
| Il4raB | TCTGCATCGACTTTTCCG | GGATCCTGGCTGTGCTGG |
| Ccl2A | GCCCTACGACGATCCTGAAAGGC | CTTACCTAGGGACATCTGCGT |
| Ccl19A | CTTGGGAAACATCGTGAAAGGC | TAGTCTGGTGAAACAAACAG |
| Ccl21A | ACTCTGAGCCTCCTGAGGCT | TAAGCGCGACTCTGACCC |
| VE-CadA | CACAGCGAACGATCGATGTATCC | GGTACCTAGTTGGGTTGTC |
| HprtB | GTTAACCGAATACAAACAAA | AAGGCGATATCCAACAAAAT |

*Primers were designed with Primer Blast website tool. Primes were described in ref. 5.
Study approval. The Institutional Animal Care and Use Committee at Harvard Medical School (IACUC protocol 04911) approved this study.

Author contributions
KU designed, performed and analyzed the majority of the experiments. DA, VC, AG, KT, RL, UHVA, JE, and AOA contributed with ideas and experimental support. AOA supervised the design and interpretation of the results. KU, JE, and AOA wrote the manuscript with the help of DA, VC, AG, KT, RL and UHVA.

Acknowledgments
This work was supported by grants from the Scleroderma Foundation and Burroughs Wellcome Fund (to AOA), US National Institutes of Health (P01 AI045757 and R21 CA182598 to VC), and the Cancer Research Institute (to VC). This work was also partly supported by the US NIH grants P01 AI112521 and R01 AI111595 (to UHVA); ST32 HL066987 (to DA); and R03 AR066357-01A1 (to JE). Additional support to UHVA was provided by U19AI095261 and the Ragon Institute of MGH, MIT, and Harvard. This work was also supported by NIH, National Institute of Arthritis Musculoskeletal and Skin Disease grants: 5P30AR061271 and 2R01AR051089 to RL. We thank Joao Pereira for his helpful discussions and for providing the WEHI-S1PR1-Flag-hCD4 B cell line.

Address correspondence to: Antonios O. Aliprantis, Merck Research Laboratories, 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, USA. Phone: 617.992.3040. E-mail: antonios.aliprantis@gmail.com or aaliprantis@partners.org.

1. Elhai M, Meune C, Avouac J, Kahan A, Allanoire Y. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. *Rheumatology* (Oxford). 2012;51(6):1017–1026.
2. Allanoire Y, Distler O. Systemic sclerosis in 2014: Advances in cohort enrichment shape future of trial design. *Nat Rev Rheumatol*. 2015;11(2):72–74.
3. Milano A, et al. Molecular subsets in the gene expression signatures of scleroderma skin. *PLoS One*. 2008;3(7):e2696.
4. Ruzeck MC, Jha S, Ledbetter S, Richards SM, Garman RD. A modified model of graft-versus-host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease. *Arthritis Rheum*. 2004;50(4):1319–1331.
5. Greenblatt MB, et al. Interspecies comparison of human and murine scleroderma reveals IL-13 and CCL2 as disease subset-specific targets. *Am J Pathol*. 2012;180(3):1080–1094.
6. Sargent JL, et al. Interspecies comparative genomic identifies optimal mouse models of systemic sclerosis. [published online ahead of print March 24, 2016] *Arthritis Rheumatol*. doi: 10.1002/art.39658.
7. Wynn TA. Type 2 cytokines: mechanisms and therapeutic strategies. *Nat Rev Immunol*. 2015;15(5):271–282.
8. LaPorte SL, et al. Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. *Cell*. 2008;132(2):259–272.
9. Malhotra D, et al. Transcriptional profiling of stroma from inflamed and resting lymph nodes defines immunological hallmarks. *Nat Immunol*. 2012;13(5):499–510.
10. Wysocki CA, Panoskaltsis-Mortari A, Blazar BR, Serody JS. Leukocyte migration and graft-versus-host disease. *Blood*. 2005;105(11):4191–4199.
11. Masopust D, Schenkel JM. The integration of T cell migration, differentiation and function. *Nat Rev Immunol*. 2013;13(5):309–320.
12. Förster R, Davalos-Misslitz AC, Rot A. CCR7 and its ligands: balancing immunity and tolerance. *Nat Rev Immunol*. 2015;15(5):271–282.
13. Pham TH, Okada T, Matloubian M, Lo CG, Cyster JG. S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress. *Immunity*. 2008;28(1):122–133.
14. Cyster JG, Schwab SR. Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. *Annu Rev Immunol*. 2012;30:69–94.
15. Mandal S, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. *Science*. 2002;296(5566):346–349.
16. Pappu R, et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. *Science*. 2007;316(5822):295–298.
17. Pham TH, et al. Lymphatic endothelial cell sphingosine kinase activity is required for lymphocyte egress and lymphatic patterning. *J Exp Med*. 2010;207(1):17–27.
18. Spiegel S, Mülsten S. The out and the ins of sphingosine-1-phosphate in immunity. *Nat Rev Immunol*. 2011;11(6):403–415.
19. Nagahashi M, et al. Sphk2, a transporter of phosphorylated sphingoid bases, regulates their blood and lymph levels, and the lymphatic network. *FASEB J*. 2013;27(3):1001–1011.
20. Kunkel GT, Maceyka M, Mülsten S, Spiegel S. Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. *Nat Rev Drug Discov*. 2013;12(9):688–702.
21. Peest U, Sensken SC, Andréani P, Hänel P, Van Veldhoven PP, Gräler MH. S1P lyase independent clearance of extracellular sphingosine 1-phosphate after dephosphorylation and cellular uptake. *J Cell Biochem*. 2008;104(3):756–772.
22. Schwab SR, Pereira JP, Matloubian M, Xu Y, Huang Y, Cyster JG. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. *Science*. 2005;309(5741):1735–1739.
23. Savetsky IL, et al. Th2 cytokines inhibit lymphangiogenesis. *PLoS One.* 2015;10(6):e0126908.

24. Shin K, et al. TH2 cells and their cytokines regulate formation and function of lymphatic vessels. *Nat Commun.* 2015;6:6196.

25. Padera TP, Stoll BR, Tooredman JB, Capen D, di Tomas E, Jain RK. Pathology: cancer cells compress intratumour vessels. *Nature.* 2004;427(6976):695.

26. Gaengel K, et al. The sphingosine-1-phosphate receptor S1PR1 restricts sprouting angiogenesis by regulating the interplay between VE-cadherin and VEGFR2. *Dev Cell.* 2012;23(3):587–599.

27. Krump-Konvalinkova V, et al. Stable knock-down of the sphingosine 1-phosphate receptor S1P1 influences multiple functions of human endothelial cells. *Atheroscler Thromb Vasc Biol.* 2005;25(3):546–552.

28. Shin K, et al. TH2 cells and their cytokines regulate formation and function of lymphatic vessels. *Nat Commun.* 2015;6:6196.

29. Lee MJ, et al. Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. *Cell.* 1999;99(3):301–312.

30. Pfeiffer F, et al. Distinct molecular composition of blood and lymphatic vascular endothelial cell junctions establishes specific functional barriers within the peripheral lymph node. *Eur J Immunol.* 2008;38(8):2142–2155.

31. Gordon S. Alternative activation of macrophages. *Nat Rev Immunol.* 2003;3(1):23–35.

32. Lowenthal JW, et al. Expression of high affinity receptors for murine interleukin 4 (BSF-1) on hemopoietic and nonhemopoietic cells. *J Immunol.* 1988;140(2):456–464.

33. Fuschiotti P, Larregina AT, Ho J, Feghali-Bostwick C, Medsger TA. Interleukin-13-producing CD8+ T cells modulate dermal fibrosis in patients with systemic sclerosis. *Arthritis Rheum.* 2013;65(1):236–246.

34. Oh MH, et al. IL-13 induces skin fibrosis in atopic dermatitis by thymic stromal lymphopoietin. *J Immunol.* 2011;186(12):7232–7242.

35. Taylor PA, et al. Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD). *Blood.* 2007;110(9):3480–3488.

36. Kopf M, Bachmann MF, Marsland BJ. Averting inflammation by targeting the cytokine environment. *Nat Rev Drug Discov.* 2010;9(9):703–718.

37. Plano D, Amin S, Sharma AK. Importance of sphingosine kinase (SphK) as a target in developing cancer therapeutics and recent developments in the synthesis of novel SphK inhibitors. *J Med Chem.* 2014;57(13):5509–5524.

38. Fletcher AL, et al. Reproducible isolation of lymph node stromal cells reveals site-dependent differences in fibroblastic reticular cells. *Front Immunol.* 2011;2:35.